OKUR logo

ONKURE THERAPEUTICS INC-A

OKURNASDAQ
🏆 #4057 by market capEarnings Nov 4US Equity
$232.15▼ $4.69 (−2.02%)
Simulated price
🔔
Track OKUR
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$109M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair
No chart data available for OKUR.

Trading Snapshot

Day Range
$229.56 – $235.96
52-Week Range
$2.23 – $5.38
Volume
$1.59B
Avg Volume
$2.03B
Shares Outstanding
40.5M
Next Earnings
Oct 31, 2026

Fundamentals Snapshot

Annual Revenue
$16M
Last Q Revenue
$4M
P/E Ratio
-0.8
P/S Ratio
0.0x
EPS (TTM)
$-1.18
Dividend Yield
0.00%
Dilution (1yr)
+1.3%

Why Investors Own OKUR

  • ✓High-growth profile — revenue up -6.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 78% gross margin and 26% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

OKUR logo

ONKURE THERAPEUTICS INC-A

OKUR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$63M▲ +15.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$52M▲ +1.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
13.5M▲ +1.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$59M▼ −$51M YoY
StockOtter · stockotter.space

About ONKURE THERAPEUTICS INC-A

OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$257.59
▲ +11.0% Upside
High Target$318.91
Low Target$195.19
Based on 30 analysts

Latest News & Updates

🚀
Reuters·2h ago

ONKURE THERAPEUTICS INC-A tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift OKUR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

ONKURE THERAPEUTICS INC-A announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.